246 related articles for article (PubMed ID: 25453968)
1. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.
Sun R; Liu Y; Li SY; Shen S; Du XJ; Xu CF; Cao ZT; Bao Y; Zhu YH; Li YP; Yang XZ; Wang J
Biomaterials; 2015 Jan; 37():405-14. PubMed ID: 25453968
[TBL] [Abstract][Full Text] [Related]
2. All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis.
Liu Y; Yu F; Dai S; Meng T; Zhu Y; Qiu G; Wen L; Zhou X; Yuan H; Hu F
Mol Pharm; 2021 Nov; 18(11):3966-3978. PubMed ID: 34579532
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
4. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells.
Sun R; Shen S; Zhang YJ; Xu CF; Cao ZT; Wen LP; Wang J
Biomaterials; 2016 Oct; 103():44-55. PubMed ID: 27376558
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles.
Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J
Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds.
Sun TM; Wang YC; Wang F; Du JZ; Mao CQ; Sun CY; Tang RZ; Liu Y; Zhu J; Zhu YH; Yang XZ; Wang J
Biomaterials; 2014 Jan; 35(2):836-45. PubMed ID: 24144908
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy.
Shen S; Sun CY; Du XJ; Li HJ; Liu Y; Xia JX; Zhu YH; Wang J
Biomaterials; 2015 Nov; 70():71-83. PubMed ID: 26302232
[TBL] [Abstract][Full Text] [Related]
12. [All-trans retinoic acid effectively inhibits breast cancer stem cells growth in vitro].
Zeng WG; Hu P; Wang JN; Liu RB
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):89-93. PubMed ID: 23714660
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
14. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
16. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
17. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.
Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P
Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X
Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
[TBL] [Abstract][Full Text] [Related]
20. A novel double-targeted nondrug delivery system for targeting cancer stem cells.
Qiao S; Zhao Y; Geng S; Li Y; Hou X; Liu Y; Lin FH; Yao L; Tian W
Int J Nanomedicine; 2016; 11():6667-6678. PubMed ID: 27994463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
